[1]王镜涵,白欣冉,董彦慧,等.A型肉毒素与曲安奈德治疗瘢痕疙瘩的长期疗效对比[J].中国皮肤性病学杂志,2019,(10):1149-1152.[doi:10.13735/j.cjdv.1001-7089.201811161]
 WANG Jinghan,BAI Xinran,DONG Yanhui,et al.Comparison of Long-term Efficacy of Botulinum Toxin Type A and Triamcinolone Acetonide for Keloid[J].The Chinese Journal of Dermatovenereology,2019,(10):1149-1152.[doi:10.13735/j.cjdv.1001-7089.201811161]
点击复制

A型肉毒素与曲安奈德治疗瘢痕疙瘩的长期疗效对比
分享到:

《中国皮肤性病学杂志》[ISSN:1001-7089/CN:61-1197/R]

卷:
期数:
2019年10期
页码:
1149-1152
栏目:
临床经验
出版日期:
2019-09-13

文章信息/Info

Title:
Comparison of Long-term Efficacy of Botulinum Toxin Type A and Triamcinolone Acetonide for Keloid
文章编号:
1001-7089(2019)10-1149-04
作者:
王镜涵白欣冉董彦慧曹哲崔久林梁晓琴
潍坊医学院整形外科医院,山东 潍坊 261000
Author(s):
WANG JinghanBAI XinranDONG YanhuiCAO ZheCUI JiulinLIANG Xiaoqin
(Plastic Surgery Institute of Weifang Medical University,Weifang 261000,China)
关键词:
A型肉毒素 曲安奈德 X线治疗 瘢痕疙瘩
Keywords:
Type A botulinum toxin Triamcinolone X-ray therapy Keloid
分类号:
R 622
DOI:
10.13735/j.cjdv.1001-7089.201811161
文献标志码:
B
摘要:
目的 比较A型肉毒素与曲安奈德治疗瘢痕疙瘩的长期疗效。方法 将30例瘢痕疙瘩患者随机分为A组和B组,各15例。A组瘢痕内注射A型肉毒素,总量不超过100 U/人,间隔8周注射1次,共治疗5次; B组行曲安奈德注射治疗,控制单次给药量<80 mg,每4周注射1次,共治疗5次; 两组患者每次注射治疗后,再行局部X线照射治疗,4 Gy/次。应用温哥华瘢痕评分量表(VSS)与可视对比评分量表(VAS)对两组治疗前后瘢痕疙瘩的整体情况进行评分,将两个量表的评分相加得出瘢痕疙瘩总评分,比较两组患者治疗前后总评分差值与治疗后的显效程度。结果 两组患者在治疗后,观察者随访24~36个月,平均(29.67±2.28)个月,均有较为理想的治疗效果。A组显效程度高于B组(P=0.01); A组治疗前后总评分差值为(8.47±0.92)分,B组治疗前后总评分差值为(5.27±1.44)分,两组差异有统计学意义(P<0.05)。其中,A组治疗后VAS评分均较治疗前有较大改善,VAS前后差值为(4.33±0.49)分,而B组治疗前后VAS评分差值变化不明显,VAS前后差值为(0.87±0.83)分,差异有统计学意义(P<0.05)。结论 在改善患者的痛痒症状和瘢痕疙瘩外观方面,采用A型肉毒素联合X线治疗瘢痕疙瘩,整体来说优于曲安奈德联合X线,疗效较好。
Abstract:
Objective To compare the long-term efficacy of botulinum toxin type A(BTA)and triamcinolone acetonide for keloid.Methods Thirty patients with keloids were randomly divided into groups A and B. Group A received BTA(≤100 U/person)once every 8 weeks and 5 times in total,while group B was given triamcinolone acetonide(≤80 mg/person)once every 4 weeks and 5 times in total.Following each treatment,skin lesion was irradiated with 4Gy of X ray.Vancouver scar score scale(VSS)and visual comparison score scale(VAS)were used to evaluate the condition of keloid before and after treatment.The total keloid scores were obtained by adding the scores of the two scales.The difference in the total scores before and after treatment,and efficacy were compared between the two groups.Results Both groups achieved satisfactory outcome following 24~36 months of follow-up(average 29.67±2.28 months of follow-up).Efficacy was higher in group A than in group B(P=0.01).The differences in total scores before and after treatment in group A were more significant than that in group B(8.47±0.92 vs. 5.27±1.44,P< 0.05).Following the treatments,the differences in VAS scores before and after treatments were also more significant in group A than in group B(4.33±0.49 vs. 0.87±0.83,P<0.05).Conclusion Botulinum toxin type A combined with X-ray is superior to triamcinolone acetonide combined with X-ray for keloid in relieving pain and pruritus in addition to superior efficacy.

参考文献/References:

[1] Arima J,Ogawa R,Iimura T,et al.Relationship between keloid and hypertension[J].J Nippon Med Sch,2012,79(6):494-495.
[2] 杨宏凤,高鸽,孙然,等.瘢痕疙瘩发病机制及外科治疗进展[J].中华实验外科杂志,2013,30(7):1543-1544.
[3] 曲春安,李敏,李东岳,等.维拉帕米与曲安奈德注射治疗瘢痕疙瘩的疗效比较[J].中国美容整形外科杂志,2018,29(6):366-368.
[4] 赵庆利,孟如松,刘淑萍,等.瘢痕疙瘩不同分型皮损的血流及血管状况检测[J].中国美容医学,2010,19(4):542-545.
[5] Perdanasari AT,Lazzeri D,Su W,et al.Recent developments in the use of intralesional injections keloid treatment[J].Arch Plast Surg,2014,41(6):620-629.
[6] 中国整形美容协会瘢痕医学分会常务委员会专家组.中国瘢痕疙瘩临床治疗推荐指南[J].中国美容整形外科杂志,2018,29(5):3-14.
[7] 郭琪格,姚敏.瘢痕疙瘩病灶内药物注射治疗的研究进展[J].中华烧伤杂志,2018,34(6):415-418.
[8] Ogawa R,Akaishi S.Endothelial dysfunction may play a key role in keloid and hypertrophic scar pathogenesis-Keloids and hypertrophic scars may be vascular disorders[J].Med Hypotheses,2016,96(9):51-60.
[9] 金哲虎.瘢痕疙瘩的成因及治疗新进展[J].中国医学文摘·皮肤科学,2015,32(1):11-15.
[10] Shaarawy E,Hegazy RA,Abdel Hay RM.Intralesional botulinum toxin type A equally effective and better tolerated than intralesionlsteroid in the treatment of keloids:a randomized controlled trial[J].J Cosmet Dermatol,2015,14(2):161-166.
[11] Khansa I,Harrison B,Janis JE.Reply:evidence-based scar management:how to improve results with technique andtechnology[J].Plast Reconstr Surg,2017,139(6):1372e-1373e.
[12] Lee HJ,Jang YJ.Recent understandings of biology,prophylaxisand treatment strategies for hypertrophic scars and keloids[J].Int J Mol Sci,2018,19(3):711-729.
[13] Park JH,Chun JY,Lee JH.Laser-assisted topical eorticosteroid delivery for the treatment of keloids[J].Lasers Med Sei,2017,32(3):601-608.
[14] Kant SB,Van den Kerckhove E,Celia C,et al.A new treatment of hypertrophic and keloid scars with combined tfiamcinolone and verapamih a retrospective study[J].Eur J Hast Surg,2018,41(1):69-80.
[15] 李新技,夏廷毅,常冬姝,等.三种不同方法治疗瘢痕疙瘩的疗效比较[J].中国美容医学,2011,20(6):949-951.
[16] 王文婷,刘涛,宋海峰,等.浅层电子线放射治疗背部瘢痕疙瘩的体外实验与临床疗效观察[J].中国美容医学,2018,27(7):87-90.
[17] 周明伟,王连有,姜日花,等.A型肉毒素联合疗法治疗瘢痕疙瘩临床疗效和不良反应评价[J].吉林大学学报(医学版),2017,43(2):386-390.
[18] 颜彤彤.A型肉毒毒素对挛缩性瘢痕的治疗及机理研究[D].中国人民解放军医学院,2013.
[19] 中国临床瘢痕防治专家共识制定小组.中国临床瘢痕防治专家共识[J].中华损伤与修复杂志(电子版),2017,12(6):401-406.

相似文献/References:

[1]赵奥林,杨德刚,张丽,等.皮损内注射曲安奈德序贯CO2点阵激光治疗增生性瘢痕疗效观察[J].中国皮肤性病学杂志,2016,(09):905.[doi:10.13735/j.cjdv.1001-7089.201603024]
 ZHAO Ao-lin,YANG De-gang,ZHANG Li,et al.Clinical Efficacy of Intralesional Injection of Triamcinolone Acetonide Plus Sequential Fractional CO2 Laser for Hypertrophic Scars[J].The Chinese Journal of Dermatovenereology,2016,(10):905.[doi:10.13735/j.cjdv.1001-7089.201603024]
[2]张敬东,杨海晶,陈梅,等.A型肉毒素治疗额横纹剂量探讨[J].中国皮肤性病学杂志,2013,(07):41.
 ZHANG Jing-dong,YANG Hai-jing,CHEN Mei,et al.A Dose Observation of Botulinum Toxin Type A(BTXA)on Horizontal Forehead Rhytides[J].The Chinese Journal of Dermatovenereology,2013,(10):41.
[3]唐智慧,刘超,贝宏,等.曲安奈德局封治疗多发性皮肤平滑肌瘤1例[J].中国皮肤性病学杂志,2013,(01):44.
[4]崔晶,金珊,南美兰,等.A型肉毒素下调UVB诱导的HaCaT细胞炎症因子的表达[J].中国皮肤性病学杂志,2019,(10):1121.[doi:10.13735/j.cjdv.1001-7089.201901123]
 CUI Jing,JIN Shan,NAN Meilan,et al.Botulinum Toxin Type A Down-regulates UVB-induced Expression of Inflammatory Cytokines in HaCaT Cells[J].The Chinese Journal of Dermatovenereology,2019,(10):1121.[doi:10.13735/j.cjdv.1001-7089.201901123]

备注/Memo

备注/Memo:
[作者单位] 潍坊医学院整形外科医院,山东 潍坊 261000
[通讯作者] 梁晓琴,E-mail:liangxq2002@163.com
更新日期/Last Update: 2019-09-12